Skip to main content

Can you take Linvoseltamab with Quadramet?

1 drug interaction and 5 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Major drug interactions

Major:

samarium sm 153 lexidronam linvoseltamab

Applies to: Quadramet (samarium sm 153 lexidronam) and linvoseltamab

Using samarium sm 153 lexidronam together with linvoseltamab may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

5 potential interactions Applies to: 5 conditions, including Liver Disease, Infection, Immunodeficiency, Neutropenia, and Renal Dysfunction.

Immunodeficiency

Moderate:

linvoseltamab

Linvoseltamab has a moderate potential interaction with Immunodeficiency.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Infection

Moderate:

linvoseltamab

Linvoseltamab has a moderate potential interaction with Infection.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Liver Disease

Moderate:

linvoseltamab

Linvoseltamab has a moderate potential interaction with Liver Disease.

The effect of moderate to severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal with any AST) on the pharmacokinetics of linvoseltamab is unknown. Due to the risk of hepatotoxicity with linvoseltamab, monitor liver enzymes and bilirubin at baseline and during treatment as indicated.

Neutropenia

Moderate:

linvoseltamab

Linvoseltamab has a moderate potential interaction with Neutropenia.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Renal Dysfunction

Moderate:

linvoseltamab

Linvoseltamab has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction/end-stage renal disease (CrCl 29 mL/min or less) on the pharmacokinetics of linvoseltamab is unknown.

Report options

Loading...
QR code containing a link to this page

More resources

linvoseltamab

A total of 454 drugs are known to interact with linvoseltamab.

Quadramet

A total of 223 drugs are known to interact with Quadramet.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer